Biotech & Pharma

STAT+: Trump is getting more credit than Biden for efforts to lower drug prices

27 sec read53 views0 listens

Despite both Trump and Biden administrations prioritizing drug price reductions, a KFF poll indicates that more Americans, particularly Republicans, credit Trump's efforts over Biden's for lowering prescription drug costs, highlighting a significant perception gap between policy implementation and public recognition. This disparity underscores the importance of clear communication strategies for content creators aiming to inform the public about policy impacts on healthcare affordability.

Read the full article at STAT Pharma

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

EU won't ban LGBTQ 'conversion therapy' but will push states to act

The European Union will not ban LGBTQ conversion therapy but will urge member states to take action against such practices. This approach reflects the EU's legal limitations and its preference for national-level legislation, impacting efforts to prot...

Ali Nemati

Biotech & Pharma5 days ago28 sec read

STAT+: Pharmalittle: We're reading about an FDA gender rule change, its program for one-day inspections, and more

The U.S. FDA proposed removing references to "gender" from its regulations, aiming to emphasize "biological sex," which could impact drug trials and representation of gender minorities in research. This change matters as it may alter how clinical tri...

Ali Nemati

Legal & PolicyMar 3132 sec read

Supreme Court sides with therapist in challenge to Colorado's ban on "conversion therapy"

The Supreme Court ruled that a Colorado ban on "conversion therapy" must be reviewed under strict scrutiny, siding with therapist Kaley Chiles who argued the ban discriminates based on her expressed views. This decision impacts developers and tech pr...

Ali Nemati

Biotech & PharmaMar 2428 sec read

STAT+: The potential loophole in Trump's plan to get other countries to pay more for drugs

A top Trump administration official revealed a potential flaw in the plan to use most-favored nation deals for drug pricing, suggesting it aims to raise prices abroad rather than lower them in the U.S., which could be ineffective if the policy's term...

Ali Nemati

CybersecurityMar 1826 sec read

Wrapping Sigstore, in-toto, and SLSA: Where Modern Supply-Chain Security Still Fails

Modern supply-chain security frameworks like Sigstore, in-toto, and SLSA enhance artifact signing, provenance metadata, and policy enforcement but fail to verify human intent behind actions. This oversight allows attackers to manipulate compliant pip...

Ali Nemati

STAT+: Trump is getting more credit than Biden for efforts to lower drug prices

Related Articles

EU won't ban LGBTQ 'conversion therapy' but will push states to act

STAT+: Pharmalittle: We're reading about an FDA gender rule change, its program for one-day inspections, and more

Supreme Court sides with therapist in challenge to Colorado's ban on "conversion therapy"

STAT+: The potential loophole in Trump's plan to get other countries to pay more for drugs

Wrapping Sigstore, in-toto, and SLSA: Where Modern Supply-Chain Security Still Fails